Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin
Status:
Unknown status
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
To compare the efficacy of Generex Oral-lyn™ RapidMist™ System and standard regular human
insulin therapy as measured by HbA1c, in type-1 diabetes mellitus subjects on BID NPH
intermediate acting insulin therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Generex Biotechnology Corp.
Collaborators:
ACM Pivotal Global Central Laboratory eResearch Technology, Inc. Hoffmann-La Roche Nextrials, Inc. OSMOS Clinical Research, Inc PSI Pharma Support Intl